Indian private university serving as a South Asian clinical and community-research partner for EU health consortia on vaccines, cancer screening, and AI-supported public health.
Manipal Academy of Higher Education (MAHE) is one of India's largest private universities, with a strong medical and health sciences wing that makes it a natural extra-European partner for EU health research consortia. In H2020 they contributed clinical and epidemiological capacity — running influenza vaccine evaluation work and community-based cervical cancer screening trials in low-resource settings. They also brought doctoral training capacity to a structured international PhD school. Their value to EU consortia is access to Indian patient populations, clinical infrastructure, and researchers trained to European standards.
Participant in ENDFLU (2020-2026), evaluating rationally designed protein- and MVA-based influenza vaccines through preclinical work and a Phase 1 controlled human infection model trial.
International partner in PRESCRIP-TEC (2021-2024), deploying community-based HPV testing and AI-assisted protocol uptake for cervical cancer prevention.
PRESCRIP-TEC applies artificial intelligence to improve screening protocol uptake in non-communicable disease prevention.
Partner in BIGSSS-departs (2016-2021), a Bremen-based MSCA-COFUND doctoral school with inter-sectorial training in the social sciences.
Both ENDFLU and PRESCRIP-TEC use MAHE as an Indian clinical/community research site for EU-led health programmes.
In 2016-2018 MAHE's visible H2020 footprint was in the social sciences, acting as an international partner in a Bremen doctoral school under MSCA-COFUND. From 2020 onwards the profile shifts decisively into health research — first as a clinical partner on next-generation influenza vaccines, then on community-based cervical cancer screening with AI-supported protocols. The trajectory is from training infrastructure to frontline clinical and public-health research.
MAHE is positioning itself as a go-to non-EU clinical and community-health research partner for consortia that need trial sites, patient access, or real-world validation in South Asia.
MAHE never coordinates in this dataset — they join as partner, participant, or explicitly "international partner," which is typical for a non-EU university accessing Horizon funding. They engage in fairly large consortia (41 unique partners across 17 countries from just 3 projects), suggesting each project is multi-country rather than bilateral. Expect them to deliver a specific work package, usually tied to Indian sites or South Asian evidence, rather than drive overall project management.
Connected to 41 distinct partner organisations across 17 countries through only three projects, indicating each consortium is broad and internationally diverse. The network is anchored in European health consortia with India as the key non-EU node.
MAHE is one of the few Indian universities repeatedly brought into EU health consortia as a formal international partner, not merely a courtesy collaborator. Compared with other HES institutions, their differentiator is the combination of a large teaching hospital network, access to South Asian patient populations, and demonstrated ability to run clinical and community trials to EU standards. For consortium builders, they are a realistic route to generating non-European evidence in vaccine, cancer, and AI-health projects.
